Oral kavite ve orofarengeal skuamöz hücreli kanserlerinde p16 pozitifliğinin etkisi

Abstract

Objective: To determine the frequency of p16 positivity in oral cavity and oropharyngeal squamous cell carcinoma (OC/OP-SCC) and to reveal whether there is a difference between p16-positive and -negative cases according to clinicopathological parameters.
Methods: p16 antibody was retrospectively analyzed immunohistochemically in biopsies of 60 patients with OC/OP-SCC operated between 2007 to 2015. Comparison was performed for age, sex, smoking habit, alcohol consumption, site of the tumor, the level of keratinization, T stage, lymphovascular invasion, perineural invasion, recurrence of the tumor, and survival.
Results: Of the 60 patients (18 females, 42 males), the median was 58 (range: 27 to 75) years. Seventeen patients were p16-positive, and 43 patients were p16-negative. Comparison of p16-positive and p16-negative groups according to age, sex, T-stage, tumor subsite, tumor profundity, lymphovascular invasion, perineural invasion and survival was not statistically significant (p>0.05). We found statistical difference between two groups according to tumor recurrence, smoking habit, and the degree of keratinization.
Conclusion: In patients who underwent surgical treatment after the diagnosis of zOC/OP-SCC, p16 positivity may have a predictive role in terms of tumor recurrence.

Keywords

• oral kavite kanseri,kanser,p16 pozitifliği,p16 positivity,oral cavity cancer,oropharyngeal cancer

References

1. 1. Chandarana S, Lee J, Chanowski E, et al. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck 2013; 35:1083–90.
2. 2. Lewis J, Thorstad W, Chernock R, Haughey B, Yip J, Zhang Q, et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010;34:1088–96.
3. 3. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000;11:489–95.
4. 4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704–7.
5. 5. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42–55.
6. 6. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630–3.
7. 7. Ralli M, Singh S, Yadav S, Sharma N, Verma R, Sen R. Assessment and clinicopathological correlation of p16 expression in head and neck squamous cell carcinoma. J Cancer Res Ther 2016;12:232–7.
8. 8. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 2010; 5:4.

9. 9. Lazarus P, Sheikh SN, Ren Q, Schantz SP, Sten JC, Richie JP, et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1, and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998;19:509–14.
10. 10. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitoini AG, Viscidi RP et al. Human papillomavirus infection and oral cancer: a case control study in Montreal, Canada. Oral Oncol 2008;44:242–50.
11. 11. Iyer N, Dogan S, Palmer F, Rahmati R, Nixon I, Lee N, et al. Detailed analysis of clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer. Ann Surg Oncol 2015;22:4411–21.
12. 12. Lee LA, Huang C, Liao C, Lee LY, Hsueh C, Chen TC, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. Plos One 2012;7:1–11.
13. 13. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612–9.